Riik: Kanada
keel: inglise
Allikas: Health Canada
RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE)
PHARMASCIENCE INC
M05BA07
RISEDRONIC ACID
35MG
TABLET
RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35MG
ORAL
30
Prescription
BONE RESORPTION INHIBITORS
Active ingredient group (AIG) number: 0135301003; AHFS:
APPROVED
2010-07-27
_pms-RISEDRONATE (Risedronate Sodium Tablet) _ _Page 1 of 44 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr PMS-RISEDRONATE Risedronate Sodium Tablets Tablets, 35 mg and 150 mg risedronate sodium (as the hemi-pentahydrate), Oral USP Bisphosphonates PHARMASCIENCE INC. 6111 Ave. Royalmount Montréal, Québec H4P 2T4 www.pharmascience.com Submission Control Number: 269451 Date of Initial Authorization JUL 27, 2010 Date of Revision: FEB 01, 2023 _pms-RISEDRONATE (Risedronate Sodium Tablet) _ _Page 2 of 44 _ RECENT MAJOR LABEL CHANGES N/A TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED RECENT MAJOR LABEL CHANGES ............................................................................................ 2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ...................................................................... 4 1 INDICATIONS .................................................................................................................... 4 1.1 Pediatrics ....................................................................................................................... 4 1.2 Geriatrics ........................................................................................................................ 4 2 CONTRAINDICATIONS ....................................................................................................... 5 4 DOSAGE AND ADMINISTRATION ....................................................................................... 5 4.1 Dosing Considerations ................................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment .............................................................. 5 4.4 Administration ............................................................................................................ Lugege kogu dokumenti